Understanding patient preferences, values, and needs is essential to patient satisfaction and patient-centered care. Whether via telehealth or in-office treatment, today’s patients and their families want to be engaged in their care. This involves inclusion in personalized decision-making, education about their disease and treatment options, updates on care progress, and arriving at treatment decisions together.
The final episode of this CMEOCast podcast series on psoriatic arthritis (PsA) focuses on how clinicians can collaborate with each other and with their patients in order to optimize treatment regimens across the health care continuum.
At the end of this CME/CE activity, participants should be able to collaborate with patients to optimize treatment regimens across the health care continuum.
The following learning objectives pertain only to those requesting CNE or CPE credit: Identify strategies to collaborate with patients to optimize treatment regimens across the health care continuum.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Rheumatologists and dermatologists, PAs, nurse practitioners, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Dr. Armstrong reports that she receives grants or research support from AbbVie Inc.; Boehringer Ingelheim/Parexel; Bristol-Myers Squibb Company; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; Galderma; Janssen-Ortho, Inc.; Janssen Pharmaceuticals, Inc.; Kyowa Hakko Kirin; Leo Pharma Inc.; Modernizing Medicine; Novartis; Ortho Dermatologics; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharma, and UCB Pharma. She is on the speakers bureau for AbbVie Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-060-H01-P
Call us at (877) CME-PROS or (877) 263-7767.